The African American study of kidney disease and hypertension (AASK): New findings

Journal of Clinical Hypertension

Volumn 3, Issue 4, 2001, Pages 244-251

  Sica, Domenic A ^a   Douglas, Janice G ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE BESYLATE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; FUROSEMIDE; HYDRALAZINE; METOPROLOL; MINOXIDIL; RAMIPRIL; TOPROLOL XL; VERAPAMIL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIALYSIS; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MULTICENTER STUDY; NEGRO; NEPHROSCLEROSIS; PROTECTION; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AFRICAN AMERICANS; AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; FEMALE; HUMANS; HYPERTENSION; KIDNEY DISEASES; MALE; METOPROLOL; MIDDLE AGED; RAMIPRIL; TIME FACTORS;

EID: 0034886144     PISSN: 15246175     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-6175.2001.00474.x     Document Type: Article

References (26)

1. End-stage renal disease in African-American and white men. 16-year MRFIT findings
2. In-depth review: The link between hypertension and nephrosclerosis
3. The low birth weight hypothesis as a plausible explanation for the black/white difference in hypertension, non-insulin dependent diabetes, and end-stage renal disease
4. Design and baseline characteristics in African American Study of Kidney Disease and Hypertension (AASK) Pilot Study
5. Short-term effects of blood pressure and antihypertensive drug regimen on glomerular filtration rate: The African-American Study of Kidney Disease and Hypertension Pilot Study
6. Effect of ramipril vs. amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial
7. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: Is this a cause for concern?
8. Cross sectional longitudinal study of spot morning urine protein:Creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end-stage renal failure in chronic renal disease in patients without diabetes
9. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: A meta-analysis of randomized trials
10. Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency
11. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
12. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial
13. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study
14. The irbesartan type II diabetic nephropathy trial: Study design and baseline patient characteristics
15. The losartan renal protection study-rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan)
16. The Heart Outcomes Prevention Evaluation (HOPE) Study: Limitations and strengths
17. Mechanism of progression of renal disease: Current hemodynamic concepts
18. How renal cytokines and growth factors contribute to renal disease progression
19. Molecular mechanisms of angiotensin II in the kidney: Emerging role in the progression of renal disease: Beyond haemodynamics
20. Proteinuria as a mediator of tubulointerstitial injury
21. Preserving renal function in adults with hypertension and diabetes: A consensus approach
22. Microalbuminuria and prevention of renal insufficiency and cardiovascular diseases
23. Using angiotensin converting enzyme inhibitors in African-American hypertensives: A new approach to treating hypertension and preventing target-organ damage
24. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria
25. Antihypertensive treatment of patients with proteinuric renal diseases: Risks or benefits of calcium channel blockers?
26. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy